Back

Ascendis Pharma reports Week 52 gains for infants treated with TransCon CNP

Verifying
  • Ascendis Pharma reported Week 52 reACHin results for infants receiving once-weekly TransCon CNP.
  • Participants’ foramen magnum widened by a mean of 3.15 mm without decompression surgeries.
  • Ascendis reported five-year TransCon PTH results in June for adults with hypoparathyroidism.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.